BACKGROUND: Cardiovascular disease remains a major public health problem associated with high mortality. The development of these diseases is associated with many genetic and cardiovascular risk factors, so the study of a person’s genetic predisposition to the development of cardiovascular disease based on gene polymorphism remains actual. The aim of research was to study the combination of polymorphisms of the ADRB1 rs1801253, AGT rs4762, SOD2 rs4880 and CAT rs1001179 genes in healthy young people to assess individual genetic predisposition to the development of cardiovascular disease. MATERIALS AND METHODS: The study involved 33 people aged 19 to 21 years who currently had no pathology of the cardiovascular system. DNA was isolated from oral epithelial cells. Genotyping of DNA samples was determined using real-time polymerase chain reaction. RESULTS: Among those examined, 39.4% had one or two unfavorable alleles for the ADRB1, AGT genes, suggesting a genetic predisposition to the development of cardiovascular disease. Unfavorable alleles of the ADRB1 gene were more common compared to the AGT gene. Each of those examined at risk of developing cardiovascular disease had one or two alleles associated with a decrease in the functioning of enzymes of the antioxidant system. Of the 33 people, only four (12.1%) do not have an unfavorable allele for the SOD2 and CAT genes. CONCLUSIONS: We believe that the determination of polymorphisms in genes for enzymes of the antioxidant system will be an important additional criterion for earlier and more active prevention of cardiovascular disease.
Colorectal cancer is one of the most common cancers worldwide. The role of tight junction proteins in the development of this disease is currently well known. Among the large claudin family, seven representatives are involved in tumorigenesis. This review aims to analyze published data on the molecular genetic mechanisms of CLDN7 involvement in colorectal cancer pathogenesis. We summarize current information on the molecular mechanisms regulating CLDN7 expression in normal conditions and in colorectal cancer. We found that CLDN7 expression can be regulated by several mechanisms, including transcription, epigenetic and post-translational modifications modulated by oncogenic signaling pathways. Increased CLDN7 expression induces mesenchymal-to-epithelial transformation, thereby inhibiting tumorigenesis by influencing the Wnt/β-catenin, Notch, Hippo, p53, and other signaling pathways. Low expression or loss of CLDN7 expression is associated with late-stage disease and higher tumor grade. However, epigenetic regulation through methylation and microRNAs, leading to decreased CLDN7 levels, along with post-translational modification by palmitoylation and phosphorylation, promotes colorectal cancer progression. Incorporating data from molecular genetic studies on the mechanisms regulating tight junction protein function is essential for developing modern treatments for patients with colorectal cancer.
Multifactorial diseases pose a growing challenge to global healthcare due to their rapidly increasing prevalence, high mortality rates, and significant contribution to disability among the working-age population. Intensive research aimed at improving early diagnosis, prevention, and treatment has underscored the critical role of epigenetic changes, which influence gene expression without altering the primary DNA sequence. This article provides an overview of the primary epigenetic mechanisms involved in gene expression regulation, including DNA methylation, post-translational histone modifications, and the role of non-coding microRNAs in gene silencing. Epigenetic factors serve as a bridge between the genome and environmental influences. Environmental risk factors—shaped by lifestyle, behavior, ecological exposures, and psycho-emotional stress—play a significant role in the phenotypic manifestations of diseases and overall human health. The reversibility of epigenetic mechanisms regulating gene expression can lead to both beneficial and adverse health outcomes. The continuous development of new technologies positions epigenetics as a promising field for functional research, with the potential to fundamentally transform therapeutic approaches to the treatment of multifactorial diseases.
30 September 2025 in Nauka Molodykh (Eruditio Juvenium)
INTRODUCTION: Currently, there is an urgent issue of safe and minimally invasive administration of medical drugs ensuring rapid and selective delivery of them to the target organs. This review considers the experience of intranasal administration of drugs from different groups, such as NSAID, hormonal agents and anticonvulsants. AIM: Based on the analysis of the scientific medical literature, to describe the current data concerning the use of medical drugs with intranasal administration and consider the possibility of intranasal use of paracetamol. An analysis of publications found in eLibrary, Scopus, PubMed databases using Google Scholar and Web of Science search engines have been conducted. In total, more than 100 sources have been examined with most significant ones included in the reference list. CONCLUSION: Of interest for us is the possibility of intranasal route of administration of paracetamol in view of its widespread use in different groups of patients. Intranasal administration eliminates the phenomenon of the primary passage of the drug through the liver, thus achieving its higher serum concentrations. Currently, most researchers tend to explain the mechanism of paracetamol action through realization of central effects. Paracetamol metabolism in the liver, involving cytochrome system isoenzymes, produces toxic metabolites conditioning the main adverse reactions of the drug, which limits its use in patients with impaired function of excretory organs.The development of a pharmaceutical form for intranasal administration of paracetamol may provide an opportunity to avoid toxicity and other undesirable effects of the drug and expand the groups of patients indicated for use of this drug, and will probably allow for a reduction in the therapeutic dose when administered.